BioInvent International AB (DE:BIX0)
FRANKFURT:BIX0
Earnings Data
Report Date
Aug 27, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
0.05Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.Company Guidance
Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)
Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.
Robust BI-1808 single-agent activity in T‑cell lymphoma (CTCL)
Monotherapy data in CTCL: 46% ORR and 92% DCR in 13 evaluable CTCL patients, with durable responses (including a complete response in Sézary Syndrome lasting >1 year); EMA orphan drug designation granted for BI-1808 in CTCL.
BI-1206 triplet shows high activity in non-Hodgkin lymphoma
Triplet (BI-1206 + rituximab + acalabrutinib) across follicular, marginal zone and mantle cell lymphoma: maintained ~80% ORR and 100% disease control rate; incremental 4 partial responses and 1 additional stable disease vs prior dataset, demonstrating activity across subtypes and encouraging duration.
Promising solid tumor signals for BI-1206 and advancement to first-line studies
Dose-escalation signals in PD-1/PD-L1 refractory solid tumors (complete and partial responses) supported opening a Phase IIa first-line program with pembrolizumab in non‑small cell lung cancer (NSCLC) and uveal melanoma; first readout expected H2 2026.
Strategic collaborations with large pharma
Supply and collaboration agreements in place with Merck (pembrolizumab combinations) and AstraZeneca (acalabrutinib supply for NHL), enabling first-line combination studies and providing strong external validation for programs.
Dense forward-looking clinical milestone timetable
Multiple near-term catalysts: additional BI-1808 combo and monotherapy Phase IIa readouts mid/late 2026; BI-1206 NHL update mid-2026; first-line BI-1206+KEYTRUDA readout H2 2026; potential pivotal starts in 2027 contingent on data.
Board strengthening and scientific depth
Two experienced board nominees (Kate Hermans, Scott Zinober) and publication of mechanistic/preclinical work that deepens scientific credibility and supports partnering discussions.
Improved full-year net sales (driven by one-time items) and short-term liquidity
Net sales for Jan–Dec 2025 were SEK 226 million vs SEK 45 million in 2024 (increase of SEK 181 million, ~+402%), driven mainly by a SEK 20 million payment (XOMA Royalty transaction) and a SEK 1 million milestone; liquid funds and current investments SEK 593 million at 31 Dec 2025 and company assessed as financed for the coming 12 months.
DE:BIX0 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:BIX0 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | €2.00 | €2.01 | +0.50% |
Feb 26, 2026 | €2.42 | €2.42 | -0.21% |
Oct 29, 2025 | €2.55 | €2.75 | +8.04% |
Aug 26, 2025 | €3.25 | €3.02 | -7.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioInvent International AB (DE:BIX0) report earnings?
BioInvent International AB (DE:BIX0) is schdueled to report earning on Aug 27, 2026, Before Open (Confirmed).
What is BioInvent International AB (DE:BIX0) earnings time?
BioInvent International AB (DE:BIX0) earnings time is at Aug 27, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of BioInvent International AB stock?
The P/E ratio of BioInvent International AB is N/A.
What is DE:BIX0 EPS forecast?
DE:BIX0 EPS forecast for the fiscal quarter 2026 (Q2) is -0.17.